Roche and Spark Therapeutics Inc. have completed their acquisition deal following the receipt of regulatory approval from all government authorities required by the merger agreement.
Spark Therapeutics, based in Philadelphia, Pennsylvania, is a fully integrated, commercial company committed to discovering, developing and delivering gene therapies for genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases. Spark Therapeutics will continue to operate as an independent company within the Roche Group.
Roche’s $4.8 billion buyout of Spark Therapeutics has been in the works for some time, but it’s deadline had multiple extensions to allow the U.S. Federal Trade Commission and the UK Competition and Markets Authority to complete their reviews of the acquisition.
